Literature DB >> 28880363

Apheresis technology correlates with bacterial contamination of platelets and reported septic transfusion reactions.

Anne F Eder1, Beth A Dy2, Barbara DeMerse2, Stephen J Wagner3, Susan L Stramer4, E Mary O'Neill2, Ross M Herron5.   

Abstract

BACKGROUND: Apheresis technology to collect platelet (PLT) components differs among devices. We evaluated the relationship of the plateletpheresis device with bacterial contamination and reported septic transfusion reactions. STUDY DESIGN AND METHODS: Plateletpheresis was performed using Amicus (Fenwal, a Fresenius Kabi Company) or Trima (Trima Accel, TerumoBCT) from 2010 to 2014. All donations used inlet-line sample diversion and were tested by quality control (QC; Day 1) aerobic culture. Rates of bacterial contamination and septic reactions to PLTs were calculated for both devices.
RESULTS: During the 5-year study period, plateletpheresis collections using Amicus and Trima devices totaled 1,486,888 and 671,955 donations, respectively. The rate of confirmed-positive bacterial cultures of apheresis PLT donations was significantly higher with Amicus than with Trima (252 vs. 112 per 106 donations [odds ratio {OR}, 2.3; 95% confidence interval {CI}, 1.8-2.9]). Septic transfusion reactions were caused by 30 apheresis PLT units from 25 contaminated Amicus procedures and three apheresis PLT units from three contaminated Trima procedures. The overall rate of septic reactions was significantly higher with apheresis PLT components collected with Amicus than with Trima (16.8 vs. 4.5 per 106 donations [OR, 3.8; 95% CI, 1.1-12.5]). All apheresis PLT components implicated in septic transfusion reactions had negative QC culture results incubated through Day 5 (i.e., false negatives).
CONCLUSION: Apheresis technology affects bacterial contamination of plateletpheresis collections. The device-specific, higher rate of confirmed-positive bacterial culture results also correlated with a significantly higher rate of reported septic transfusion reactions to apheresis PLTs.
© 2017 AABB.

Entities:  

Mesh:

Year:  2017        PMID: 28880363     DOI: 10.1111/trf.14308

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  10 in total

Review 1.  A Comparison of Transfusion-Related Adverse Reactions Among Apheresis Platelets, Whole Blood-Derived Platelets, and Platelets Subjected to Pathogen Reduction Technology as Reported to the National Healthcare Safety Network Hemovigilance Module.

Authors:  Sanjida J Mowla; Ian T Kracalik; Mathew R P Sapiano; Lynne O'Hearn; Chester Andrzejewski; Sridhar V Basavaraju
Journal:  Transfus Med Rev       Date:  2021-04-02

2.  Plateletpheresis-associated lymphopenia in frequent platelet donors.

Authors:  John M Gansner; Mahboubeh Rahmani; A Helena Jonsson; Brooke M Fortin; Idayat Brimah; Martha Ellis; Robin Smeland-Wagman; Zhihan J Li; Jason M Schenkel; Michael B Brenner; Revital Yefidoff-Freedman; Steven R Sloan; Nancy Berliner; Nicolas C Issa; Lindsey R Baden; Dan L Longo; Duane R Wesemann; Donna Neuberg; Deepak A Rao; Richard M Kaufman
Journal:  Blood       Date:  2018-11-14       Impact factor: 22.113

3.  Acquired platelet storage container leaks and contamination with environmental bacteria: A preventable cause of bacterial sepsis.

Authors:  Richard R Gammon; Rita A Reik; Marc Stern; Ralph R Vassallo; Dan A Waxman; Pampee P Young; Richard J Benjamin
Journal:  Transfusion       Date:  2021-12-20       Impact factor: 3.337

4.  The argument(s) for lowering the US minimum required content of apheresis platelet components.

Authors:  Richard J Benjamin; Louis Katz; Richard R Gammon; Susan L Stramer; Eva Quinley
Journal:  Transfusion       Date:  2018-11-21       Impact factor: 3.157

5.  Fatal Sepsis Associated with Bacterial Contamination of Platelets - Utah and California, August 2017.

Authors:  Roberta Z Horth; Jefferson M Jones; Janice J Kim; Bert K Lopansri; Sarah J Ilstrup; Joy Fridey; Walter E Kelley; Susan L Stramer; Ashok Nambiar; Lynn Ramirez-Avila; Amy Nichols; Wendy Garcia; Kelly F Oakeson; Nicholas Vlachos; Gillian McAllister; Robert Hunter; Allyn K Nakashima; Sridhar V Basavaraju
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-06-29       Impact factor: 17.586

6.  Sepsis Attributed to Bacterial Contamination of Platelets Associated with a Potential Common Source - Multiple States, 2018.

Authors:  Sydney A Jones; Jefferson M Jones; Vivian Leung; Allyn K Nakashima; Kelly F Oakeson; Amanda R Smith; Robert Hunter; Janice J Kim; Melissa Cumming; Eileen McHale; Pampee P Young; Joy L Fridey; Walter E Kelley; Susan L Stramer; Stephen J Wagner; F Bernadette West; Ross Herron; Edward Snyder; Jeanne E Hendrickson; David R Peaper; Adi V Gundlapalli; Charles Langelier; Steve Miller; Ashok Nambiar; Morvarid Moayeri; Jack Kamm; Heather Moulton-Meissner; Pallavi Annambhotla; Paige Gable; Gillian A McAllister; Erin Breaker; Erisa Sula; Alison Laufer Halpin; Sridhar V Basavaraju
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-06-14       Impact factor: 17.586

7.  Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects.

Authors:  Konrad Rosskopf; Wolfgang Helmberg; Peter Schlenke
Journal:  Transfusion       Date:  2020-07-03       Impact factor: 3.157

8.  Investigating Transfusion-related Sepsis Using Culture-Independent Metagenomic Sequencing.

Authors:  Emily Crawford; Jack Kamm; Steve Miller; Lucy M Li; Saharai Caldera; Amy Lyden; Deborah Yokoe; Amy Nichols; Nam K Tran; Sarah E Barnard; Peter M Conner; Ashok Nambiar; Matt S Zinter; Morvarid Moayeri; Paula Hayakawa Serpa; Brian C Prince; Jenai Quan; Rene Sit; Michelle Tan; Maira Phelps; Joseph L Derisi; Cristina M Tato; Charles Langelier
Journal:  Clin Infect Dis       Date:  2020-08-22       Impact factor: 9.079

9.  The pursuit of platelet safety.

Authors:  Paul M Ness
Journal:  Transfusion       Date:  2022-05-04       Impact factor: 3.337

Review 10.  Bacterial contamination of platelets for transfusion: strategies for prevention.

Authors:  Jerrold H Levy; Matthew D Neal; Jay H Herman
Journal:  Crit Care       Date:  2018-10-27       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.